Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis

(2016) Aksana K. Jones et al.   AAPS Journal

BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199

(2016) K. Bojarczuk et al.   BLOOD

Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor

(2016) Ahmed Hamed Salem et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study

(2016) Suresh K. Agarwal et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma

(2016) Ahmed Hamed Salem et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

(2016) Stephan Stilgenbauer et al.   LANCET ONCOLOGY

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

(2016) Andrew W. Roberts et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

(2016) M. Konopleva et al.   Cancer Discovery

Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment

(2015) Michael Hallek   AMERICAN JOURNAL OF HEMATOLOGY

Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib

(2015) J. C. Byrd et al.   BLOOD

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib

(2015) P. Jain et al.   BLOOD

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

(2015) Joel D. Leverson et al.   Science Translational Medicine

Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma

(2015) David Chiron et al.   Oncotarget

Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib

(2014) D. Wodarz et al.   BLOOD

Entering the Era of Targeted Therapy for Chronic Lymphocytic Leukemia: Impact on the Practicing Clinician

(2014) John C. Byrd et al.   JOURNAL OF CLINICAL ONCOLOGY

Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition

(2013) Matthew S. Davids et al.   LEUKEMIA & LYMPHOMA

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Choosing first-line therapy for chronic lymphocytic leukemia

(2011) Samantha Jaglowski et al.   Expert Review of Anticancer Therapy

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD

In vivo Dynamics of Stable Chronic Lymphocytic Leukemia Inversely Correlate with Somatic Hypermutation Levels and Suggest No Major Leukemic Turnover in Bone Marrow

(2008) R. van Gent et al.   CANCER RESEARCH